Semaglutide vs Tirzepatide for Type 2 Diabetes and Prediabetes: Which Lowers HbA1c More, and Which Should You Take?
In diabetes the comparison has a second scoreboard, HbA1c, and a second consideration, the heart. Here is the head-to-head data on blood sugar, weight and cardiovascular protection, and how a doctor picks between them for an Indian patient with diabetes or prediabetes.
ALTRcare Medical Team
Clinical Editorial
Both drugs began life as diabetes medicines. Ozempic was licensed for type 2 diabetes years before Wegovy existed, and Mounjaro's first approval was for diabetes too. So for a patient with diabetes or prediabetes, the question is not only which loses more weight but which controls blood sugar better, which protects the heart, and how each fits with metformin, insulin and the other tablets already on the shelf. This article is that comparison. The general guide is here.
Blood sugar: the head-to-head
SURPASS-2 compared tirzepatide at 5, 10 and 15 mg against semaglutide 1 mg (the top Ozempic dose in India) in people with type 2 diabetes on metformin, for 40 weeks. Tirzepatide lowered HbA1c by 2.0 to 2.3 percentage points against 1.9 for semaglutide, and more patients on tirzepatide reached an HbA1c under 7 or under 5.7. Weight loss was 7.6 to 11.2 kg against 5.7 kg. The comparison is slightly unfair to semaglutide, since 1 mg is not its full dose, but the direction holds in every analysis since.
| Tirzepatide 5 / 10 / 15 mg | Semaglutide 1 mg | |
|---|---|---|
| HbA1c reduction | 2.0 / 2.2 / 2.3 points | 1.9 points |
| Reached HbA1c under 7 | 82 to 86% | 79% |
| Weight loss | 7.6 / 9.3 / 11.2 kg | 5.7 kg |
| Stomach side effects | Similar | Similar |
The heart: where semaglutide leads
Indians with diabetes get heart disease a decade earlier than Europeans, so this is not a footnote. Semaglutide has completed large cardiovascular outcome trials: SUSTAIN-6 in diabetes and SELECT in obesity without diabetes both showed about a 20 to 26% reduction in major cardiovascular events. Tirzepatide's equivalent trial, SURPASS-CVOT, reported in 2025 that tirzepatide was at least as protective as the older GLP-1 dulaglutide, which is reassuring but not the same as a placebo-controlled reduction. If you have had a heart attack, a stent, or known coronary disease, semaglutide's evidence is the more complete, and many cardiologists prefer it for that reason alone.
Prediabetes: cost decides
For prediabetes, HbA1c 5.7 to 6.4 or a fasting glucose of 100 to 125, both drugs work well and both push a large majority of people back to normal glucose within a year, mainly through weight loss. Semaglutide's prediabetes data is extensive (in STEP 1, about 85% of participants with prediabetes reverted to normal), and the cost difference is decisive when the goal is prevention rather than treatment. A prediabetic patient with BMI 28 on generic semaglutide at ₹2,500 a month is on the right drug.
Combining with what you already take
- Metformin: continues with either. Both trials were run on top of metformin.
- Sulfonylureas (glimepiride, gliclazide) and insulin: either GLP-1 raises the risk of hypoglycaemia in combination, so the doctor usually reduces the sulfonylurea or insulin dose when starting. Do not adjust these yourself.
- SGLT2 inhibitors (dapagliflozin, empagliflozin): combine well with either GLP-1; additive weight and HbA1c benefits.
- DPP-4 inhibitors (sitagliptin, vildagliptin): stopped when a GLP-1 starts; they work on the same pathway and add nothing.
How our doctors choose in diabetes
| Situation | Usually | Why |
|---|---|---|
| Prediabetes, any BMI 23+ | Semaglutide | Both revert prediabetes; cost decides |
| Type 2 diabetes, HbA1c under 8, BMI under 32 | Semaglutide | Adequate HbA1c effect; a fifth of the cost; more heart data |
| Type 2 diabetes, HbA1c above 8 or 9 | Tirzepatide if affordable | Larger HbA1c reduction; more reach target without adding insulin |
| Known heart disease, prior MI, stents | Semaglutide | Completed placebo-controlled outcome trials |
| BMI 35+ with diabetes | Tirzepatide if affordable | Weight and glucose both need the stronger drug |
| On insulin, wants to reduce it | Either; tirzepatide reduces insulin need more | Doctor lowers insulin dose as the GLP-1 takes effect |
| Kidney disease (eGFR under 60) | Semaglutide | More kidney outcome data (FLOW trial); dose needs no adjustment on either |
Diabetic eye disease
Rapid improvement in blood sugar with semaglutide caused a temporary worsening of diabetic retinopathy in some patients in SUSTAIN-6. If you have known retinopathy, tell your doctor; an eye check before starting and a slower titration are usual.
Diabetes or prediabetes with weight to lose?
Take the free 2-minute assessment and book a free consultation. Our physicians treat diabetes and weight together, and will coordinate with your existing diabetologist if you have one.
Key takeaways
- Tirzepatide lowers HbA1c more (about 2.2 vs 1.9 points) and loses roughly twice the weight in the head-to-head diabetes trial.
- Semaglutide has completed placebo-controlled heart and kidney outcome trials; tirzepatide's evidence is reassuring but less complete.
- For prediabetes and milder diabetes, generic semaglutide's cost makes it the default; tirzepatide for HbA1c above 8 or BMI 35+ if affordable.
- Sulfonylurea and insulin doses usually need reducing when a GLP-1 starts; DPP-4 inhibitors are stopped.
Frequently asked questions
Which lowers HbA1c more, semaglutide or tirzepatide?
Tirzepatide. In SURPASS-2, tirzepatide reduced HbA1c by 2.0 to 2.3 percentage points versus 1.9 for semaglutide 1 mg over 40 weeks, with roughly twice the weight loss.
Which is better for the heart?
Semaglutide has completed placebo-controlled cardiovascular outcome trials showing about a 20 to 26% reduction in major events. Tirzepatide's trial showed it was at least as protective as dulaglutide. For known heart disease, most doctors prefer semaglutide's evidence.
Can I take semaglutide or tirzepatide for prediabetes?
Yes, if your BMI is 23 or above and a doctor prescribes it. Both revert prediabetes in most people within a year, mainly through weight loss. Generic semaglutide is usually the choice on cost.
Do I stop metformin when I start a GLP-1?
Usually no; both drugs were tested on top of metformin. Sulfonylureas and insulin are often reduced to avoid low blood sugar, and DPP-4 inhibitors are stopped.
Is Mounjaro approved for diabetes in India?
Yes. Mounjaro and Yurpeak are approved by the DCGI for type 2 diabetes and for chronic weight management.
Ready to take the next step?
Take the free 2-minute eligibility assessment. A doctor reviews it before anything is prescribed — no obligation.
This article is for general educational purposes and is not a substitute for personalised medical advice. GLP-1 medications are prescription-only and not suitable for everyone. Always consult a qualified doctor before starting, changing, or stopping any treatment.
Keep reading
Medication Guide
Semaglutide vs Tirzepatide: Which One Should You Take? A Doctor's Decision Guide for India (2026)
Diabetes & Metabolic
Diabetes 'Reversal' in India: What GLP-1 Can Honestly Achieve (and What the Ads Won't Tell You)
Diabetes & Metabolic